Overview

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Pemetrexed disodium and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pemetrexed disodium together with erlotinib may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of two different schedules of pemetrexed disodium and erlotinib and to see how well they work in treating patients with advanced non-small cell lung cancer or other solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, Davis
Collaborator:
National Cancer Institute (NCI)
Treatments:
Erlotinib Hydrochloride
Pemetrexed